Evidence map›Paper›PMID 42778601›Full record

ArticleNature2026

A design approach for bitopic kinase inhibitors.

Jack W Stevenson, Kevin Lou, Joshua A Reynolds, Ian R Outhwaite, Kenneth Huang, Ivan Sokirniy, Sky Y J Peterson, Amir Z Munir, Celine D Wang, Haider Inam and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Jack W Stevenson *Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7261-4958
Kevin Lou *Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. kevin.lou@ucsf.edu.ORCID http://orcid.org/0000-0003-4939-4381
Joshua A ReynoldsDepartment of Biomedical Engineering, The Pennsylvania State University, University Park, PA, USA.
Ian R OuthwaiteDepartment of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.ORCID http://orcid.org/0000-0003-2037-3261
Kenneth HuangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
Ivan SokirniyHuck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA, USA.ORCID http://orcid.org/0000-0002-1846-5469
Sky Y J PetersonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0009-0008-8157-4941
Amir Z MunirSection of Cardio-Oncology and Immunology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0009-0009-3512-5851
Celine D WangDepartment of Chemistry, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0001-8190-1043
Haider InamDepartment of Biomedical Engineering, The Pennsylvania State University, University Park, PA, USA.
Emma L GebauerDepartment of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.ORCID http://orcid.org/0009-0003-5138-9685
Ariel Leyte-VidalDepartment of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.
Anastasiia GrynyovaDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0009-0004-6259-4024
Sydney M FigueroaDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Matthew G ReesBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2987-7581
Melissa M RonanBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4269-1404
Fernando SalangsangHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Yan ZengHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Veronica SteriHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Jennifer A RothBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5117-5586
Neil P ShahDepartment of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.
Ignacia EcheverriaDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4717-1467
Andrej ŠaliDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
Ziyang ZhangDepartment of Chemistry, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0003-0541-7211
Javid J MoslehiSection of Cardio-Oncology and Immunology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Markus A SeeligerDepartment of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, USA.ORCID http://orcid.org/0000-0003-0990-1756
Justin R PritchardDepartment of Biomedical Engineering, The Pennsylvania State University, University Park, PA, USA.
Kevan M ShokatDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. kevan.shokat@ucsf.edu.ORCID http://orcid.org/0000-0001-8590-7741

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional kinase inhibitors face a trade-off between potency and selectivity because their affinity depends on limited molecular interactions in a single highly conserved binding site. Bitopic inhibitors overcome this limitation by engaging multiple sites on the same target

Identifiers

PMID42778601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.